Home Tags TNBC

Tag: TNBC

Datopotamab Deruxtecan + Durvalumab Shows Robust and Durable Tumor Responses in...

Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan + durvalumab (Imfinzi®; AstraZeneca;  Arm 7) showed that the treatment combination demonstrated durable tumor responses without  new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer (mTNBC) with six months additional follow-up from the previous data cut-off.
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

FDA Approves Sacituzumab Govitecan for Adult Patients with Unresectable Locally Advanced...

This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...
Featured image: An aerial view of the Yangtze River Delta/Shanghai in the southern Jiangsu province and northern Zhejiang province. Photo Courtecy: 2015 - 2020 © VCG/Gettyimages. Used with permission.

Everest Medicines to Initiate a Registration Study in China for Sacituzumab...

China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...

Boehringer Ingelheim Venture Fund and PPF Group Close a US $...

Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...

Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...

Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...

Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...

Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...

Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...

Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple...

Seattle Genetics has signed a clinical collaboration agreement with Genentech, a member of the Roche Group, for the evaluation of its investigational antibody-drug conjugate...

Sacituzumab Govitecan Show Promising Results in Patients with Advanced Triple-negative Breast...

A clinical trial of an antibody-drug conjugate that combines the active portion of a chemotherapy drug with an antibody targeting a molecule expressed on...

SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...

Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...

X